

410/0  
 INFORMATION DISCLOSURE CITATION  
 Form PTO-1449 (Modified)  
 (Use several sheets if necessary)

ATTY. DOCKET NO.  
 7636-0020.30

SERIAL NO.  
 09/461, 684

APPLICANT


Laus, et al.

FILING DATE

December 14,  
 1999

GROUP

1646  
 1644



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MD	Bennett, S.R.M., et al., "Help for cytotoxic-T-cell responses is mediated by CD40 signalling" <i>Nature</i> 393:478-480 (1998).
MD	Brossart, P., et al., "Virus-Mediated Delivery of Antigenic Epitopes into Dendritic Cells as a Means to Induce CTL" <i>J. Immunol.</i> 158:3270-3276 (1997).
MD	Czerniecki, B.J., et al., "Calcium Ionophore-Treated Peripheral Blood Monocytes and Dendritic Cells Rapidly Display Characteristics of Activated Dendritic Cells" <i>J. Immunol.</i> 159:3823-3837 (1997).
MD	Greenberg, P.D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells" <i>Advances in Immunol.</i> 49:281-355 (1991).
MD	Jameson, S.C., et al., "Clone-specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-restricted Cytotoxic T Cells" <i>J. Exp. Med.</i> 177:1541-1550 (1993).
MD	Newell, M.K., et al., "Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes" <i>Proc Natl Acad Sci USA</i> 90:10459-10463 (1993).
MD	Ridge, J.P., et al., "A conditioned dendritic cell can be a temporal bridge between a CD4 <sup>+</sup> T-helper and a T-killer cell" <i>Nature</i> 393:474-478 (1998).

*Khanna N* 7/23/99



NP	Fruman, J.-P., et al., "HLA class II signaling mediates cellular activation and programmed cell death" <i>Exp Hematol</i> 24:1409-1415 (1996).
NO	Vidovic, D., et al., "Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments" <i>Eur J Immunol</i> 25:3349-3355 (1995).
EXAMINER <i>Manana D.</i> DATE CONSIDERED 7/23/01	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


## INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

ATTY. DOCK CO.  
7636-0020.30SERIAL NO.  
09/461,684

JUN 23 2000



APPLICANT

Laus, et al. TECH CENTER 1600/2900

FILING DATE  
December 14, 1999

GROUP

1646 1646

U. S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
MD	497 997 A1	08/12/92	EP			
MD	WO 96/10038	04/04/96	WIPO WO			
MD	WO 96/12009	04/25/96	WIPO WO			

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MD	Buschle, M., et al., "Transloading of tumor antigen-derived peptides into antigen-presenting cells" Proc. Natl. Acad. Sci. USA 94:3256-3261 (1997).
MD	Layton, G.T., et al., "Induction of HIV-Specific Cytotoxic T Lymphocytes In Vivo With Hybrid HIV-1 V3:Ty-Virus-Like Particles" Journal of Immunology 151(2):1097-1107 (1993).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

7/23/01